132 related articles for article (PubMed ID: 2507661)
1. Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo.
Hockertz S; Franke G; Kniep E; Lohmann-Matthes ML
J Interferon Res; 1989 Oct; 9(5):591-602. PubMed ID: 2507661
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes.
Hockertz S; Franke G; Paulini I; Lohmann-Matthes ML
J Interferon Res; 1991 Jun; 11(3):177-85. PubMed ID: 1919076
[TBL] [Abstract][Full Text] [Related]
3. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide.
Goldbach P; Dumont S; Kessler R; Poindron P; Stamm A
Am J Physiol; 1996 Mar; 270(3 Pt 1):L429-34. PubMed ID: 8638735
[TBL] [Abstract][Full Text] [Related]
4. Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE) and interferon-y (IFN-y) in experimental infection with Listeria monocytogenes.
Melissen PM; van Vianen W; Bidjai O; van Marion M; Bakker-Woudenberg IA
Biotherapy; 1993; 6(2):113-24. PubMed ID: 8398570
[TBL] [Abstract][Full Text] [Related]
5. Potent in situ activation of murine lung macrophages and therapy of melanoma metastases by systemic administration of liposomes containing muramyltripeptide phosphatidylethanolamine and interferon gamma.
Fidler IJ; Fan D; Ichinose Y
Invasion Metastasis; 1989; 9(2):75-88. PubMed ID: 2496047
[TBL] [Abstract][Full Text] [Related]
6. Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes.
Fidler IJ; Fogler WE; Kleinerman ES; Saiki I
J Immunol; 1985 Dec; 135(6):4289-96. PubMed ID: 3934281
[TBL] [Abstract][Full Text] [Related]
7. Combined liposomal immuno- and chemotherapy of visceral leishmaniasis.
Everlien H; Hockertz S
Arzneimittelforschung; 1999 Nov; 49(11):954-61. PubMed ID: 10604050
[TBL] [Abstract][Full Text] [Related]
8. Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined.
ten Hagen TL; van Vianen W; Bakker-Woudenberg IA
J Infect Dis; 1995 Feb; 171(2):385-92. PubMed ID: 7844375
[TBL] [Abstract][Full Text] [Related]
9. Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole.
Dvoroznáková E; Porubcová J; Snábel V; Fedorocko P
Parasitol Res; 2008 Sep; 103(4):919-29. PubMed ID: 18587669
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages.
Saiki I; Fidler IJ
J Immunol; 1985 Jul; 135(1):684-8. PubMed ID: 3923117
[TBL] [Abstract][Full Text] [Related]
11. Liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) promotes haemopoietic recovery in irradiated mouse.
Fedorocko P
Int J Radiat Biol; 1994 Apr; 65(4):465-75. PubMed ID: 7908934
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic study of liposome-encapsulated human interferon-gamma after intravenous and intramuscular injection in mice.
Rutenfranz I; Bauer A; Kirchner H
J Interferon Res; 1990 Jun; 10(3):337-41. PubMed ID: 2117038
[TBL] [Abstract][Full Text] [Related]
13. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ.
Pahl JH; Kwappenberg KM; Varypataki EM; Santos SJ; Kuijjer ML; Mohamed S; Wijnen JT; van Tol MJ; Cleton-Jansen AM; Egeler RM; Jiskoot W; Lankester AC; Schilham MW
J Exp Clin Cancer Res; 2014 Mar; 33(1):27. PubMed ID: 24612598
[TBL] [Abstract][Full Text] [Related]
14. Systemic activation of tumoricidal properties in mouse macrophages and inhibition of melanoma metastases by the oral administration of MTP-PE, a lipophilic muramyl dipeptide.
Fidler IJ; Fogler WE; Brownbill AF; Schumann G
J Immunol; 1987 Jun; 138(12):4509-14. PubMed ID: 3584979
[TBL] [Abstract][Full Text] [Related]
15. In vitro synergic effect of interferon gamma combined with liposomes containing muramyl tripeptide on human monocyte cytotoxicity against fresh allogeneic and autologous tumor cells.
Galligioni E; Santarosa M; Favaro D; Spada A; Talamini R; Quaia M
Tumori; 1994 Oct; 80(5):385-91. PubMed ID: 7839471
[TBL] [Abstract][Full Text] [Related]
16. Pre- and postirradiation hemopoietic effects of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) administered to C57Bl/6 mice before irradiation.
Macková NO; Fedorocko P
Neoplasma; 1993; 40(6):379-85. PubMed ID: 8289971
[TBL] [Abstract][Full Text] [Related]
17. Synergism of recombinant human interferon gamma with liposome-encapsulated muramyl tripeptide in activation of the tumoricidal properties of human monocytes.
Sone S; Tandon P; Utsugi T; Ogawara M; Shimizu E; Nii A; Ogura T
Int J Cancer; 1986 Oct; 38(4):495-500. PubMed ID: 3093390
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of NK cell activity in tissue specific sites by liposomes incorporating MTP-PE.
Talmadge JE; Schneider M; Collins M; Phillips H; Herberman RB; Wiltrout RH
J Immunol; 1985 Aug; 135(2):1477-83. PubMed ID: 4008928
[TBL] [Abstract][Full Text] [Related]
19. Muramyl tripeptide phosphatidylethanolamine encapsulated in liposomes stimulates monocyte production of tumor necrosis factor and interleukin-1 in vitro.
Maeda M; Knowles RD; Kleinerman ES
Cancer Commun; 1991; 3(10-11):313-21. PubMed ID: 1722107
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administration.
Kleinerman ES; Jia SF; Griffin J; Seibel NL; Benjamin RS; Jaffe N
J Clin Oncol; 1992 Aug; 10(8):1310-6. PubMed ID: 1634921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
